Anemia Clinical Trial
Official title:
Teff (Eragrostis Tef) as a Functional Food for the Prevention of Pregnancy Iron-deficiency Anemia
It has been estimated that 1 in 2 women expecting a baby will be diagnosed with iron
deficiency. In turn iron deficiency can affect the health and wellbeing or both mother and
child. Studies show that low iron stores prior to conception and low iron intakes during
pregnancy may both be contributing to this problem. Although dietary supplements may be one
solution, research indicates that daily compliance is low (Nguyen et al., 2008).
Furthermore, prescribed iron supplements may result in uncomfortable side-effects, including
constipation (Wulff & Ekstrom, 2003).
It is been observed in Ethiopia that iron deficiency anemia is lower than average; a finding
that has been attributed to regular "Teff" consumption (Gies et al., 2003). Teff (Eragrostis
tef) is a staple food usually consumed in the form of Enjera (flat bread prepared using a
range of cereals). Research has shown that Teff is a rich source of iron that is easily
absorbed by the body.
Although it is believed that regular Teff consumption may prevent to onset of iron
deficiency anemia there is no research to support this. Therefore, the aim of the present
study is to es-tablish whether incorporating Teff into the daily diet may be one way to
improve blood profile and prevent the onset of iron deficiency anemia in expectant mothers.
Study findings will demonstrate whether Teff may be an alternative source of iron that can
be easily incorporated into the daily diet of both pregnant mothers and the lay public.
| Status | Completed |
| Enrollment | 55 |
| Est. completion date | July 2011 |
| Est. primary completion date | July 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 40 Years |
| Eligibility |
Inclusion Criteria: - Caucasian - Primiparous - Singleton pregnancy (wk 20 to wk 30) - Non smokers - Pre pregnancy BMI between 19.8 and 26 - Healthy, free from iron metabolism disorders (pregnancy induced hypertension - Not taking medicines known to influence iron status - Not taking iron supplements (multivitamins will be accounted for) - Free from gastrointestinal disorders - No allergies Exclusion Criteria: - Pregnancy haemoglobin concentrations are not within the normal range (below 70g/l or over 160g/l) |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Manchester Food Research Centre, Manchester Metropolitan University | Manchester |
| Lead Sponsor | Collaborator |
|---|---|
| Manchester Metropolitan University |
United Kingdom,
McKenna D, Spence D, Haggan SE, McCrum E, Dornan JC, Lappin TR. A randomized trial investigating an iron-rich natural mineral water as a prophylaxis against iron deficiency in pregnancy. Clin Lab Haematol. 2003 Apr;25(2):99-103. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To develop Teff bread that is rich in iron (per slice). | 2 years | No | |
| Primary | To establish whether iron from Teff is bioavailable. | 2 years | No | |
| Primary | To conclude whether daily Teff consumption prevents iron-deficiency anemia in pregnancy. | 2 years | No | |
| Secondary | To use a range of different biomarkers to determine iron status. | 2 years | No | |
| Secondary | To compare dietary intakes of iron and iron status between the Teff/control group. | 2 years | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
| Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |